ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.
ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.
ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.
|Aug 21, 2019||ENDRA Life Sciences to Participate at Upcoming Investor Conferences|
|Aug 08, 2019||ENDRA Life Sciences Reports Second Quarter 2019 Financial & Operational Results|
|Jul 29, 2019||ENDRA Life Sciences Completes Private Placement of $2.8 Million of Convertible Secured Notes and Warrants|
|Jul 22, 2019||ENDRA Life Sciences to Host Second Quarter 2019 Results Conference Call on Thursday, August 8, 2019 at 4:30 p.m. ET|
|Jul 01, 2019||ENDRA Life Sciences and Rocky Vista University College of Osteopathic Medicine Partnering for Clinical Study of Thermo Acoustic Enhanced Ultrasound Device|
|Day Range||1.47 - 1.59|
|52 Week Range||0.90 - 5.75|
|Bid/Ask||1.54 / 1.58|
|Bid/Ask Size||1,400 X 700|
|Market Cap||11.55 million|
|Shares Outstanding||7.42 million|
|Dividend/Yield||0.00 / 0.00%|
|P/E Ratio (TTM)||N/A|